Dana Pizzuti - 20 Mar 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Med and Dev Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
20 Mar 2024
Net transactions value
-$421,970
Form type
4
Filing time
22 Mar 2024, 16:52:02 UTC
Previous filing
20 Mar 2024
Next filing
17 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $73,894 +4,375 +15% $16.89 32,875 20 Mar 2024 Direct
transaction CRNX Common Stock Sale $200,769 -4,375 -13% $45.89 28,500 20 Mar 2024 Direct
transaction CRNX Common Stock Options Exercise $168,900 +10,000 +35% $16.89 38,500 20 Mar 2024 Direct
transaction CRNX Common Stock Sale $432,800 -10,000 -26% $43.28 28,500 20 Mar 2024 Direct F1
transaction CRNX Common Stock Sale $31,195 -714 -2.5% $43.69 27,786 20 Mar 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Stock Option (right to buy) Options Exercise $0 -4,375 -2.1% $0.000000 201,667 20 Mar 2024 Common Stock 4,375 $16.89 Direct F2
transaction CRNX Stock Option (right to buy) Options Exercise $0 -10,000 -5% $0.000000 191,667 20 Mar 2024 Common Stock 10,000 $16.89 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.28 per share. The range of sales prices on the transaction date was $42.70 to $43.77 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F2 The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.